Lanean...
A case of checkpoint inhibitor-induced celiac disease
BACKGROUND: Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activation. As treatment with ICIs is becoming more common, rare irAEs are also bein...
Gorde:
| Argitaratua izan da: | J Immunother Cancer |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6683380/ https://ncbi.nlm.nih.gov/pubmed/31383006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0694-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|